Please login to the form below

Not currently logged in
Email:
Password:

UCART19

This page shows the latest UCART19 news and features for those working in and with pharma, biotech and healthcare.

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

It already has one AlloCAR candidate (UCART19) in phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL), and results from the trial could be revealed as early ... If all goes well for UCART19, it could not only

Latest news

  • Cellectis floored by patient death in CAR-T trial Cellectis floored by patient death in CAR-T trial

    The French biotech has another CAR-T therapy in clinical testing - CD19-targeting UCART19 for acute lymphoblastic leukaemia (ALL) - and this is unaffected by the clinical hold, with trials ongoing in ... UCART19 is partnered with Servier and Pfizer.

  • Servier cleared to start US trials CAR-T therapy Servier cleared to start US trials CAR-T therapy

    The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Early results from the CALM trial have already shown that UCART19 can

  • Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial

    Another allogeneic CAR-T therapy - the CD19-targeting UCART19 - is already in trials in the UK being run by partners Servier and Pfizer. ... Cellectis' UCART19 has shown positive effects in two leukaemia patients, although one suffered an episode of graft

  • Baxalta’s rare blood cancer drug Oncaspar approved in Europe Baxalta’s rare blood cancer drug Oncaspar approved in Europe

    It could also eventually see further competition from Pfizer's collaboration with Servier and Cellectis, should UCART19 - which was successfully used to treat an 11-month-old British girl with incurable,

  • Cellectis gets big pharma partners for CAR-T therapy Cellectis gets big pharma partners for CAR-T therapy

    Pfizer and Servier have joined forces to help Cellectis develop UCART19, which hit the headlines earlier this month when it was used to treat a UK girl dying of cancer. ... Pfizer and Servier will collaborate on a joint clinical development programme for

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    915. Cellectis / Servier. Licence. Product candidates for solid tumours, UCART19 (allogenic CAR-T) for leukaemia and lymphomas (6 candidates in total).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics